Patents by Inventor Zhijian Lu

Zhijian Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7935727
    Abstract: Compounds having a biphenyl group substituted with a phenyl or heteroaromatic group, as shown in Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: May 3, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yi-Heng Chen, Zhijian Lu, Peter J. Sinclair
  • Patent number: 7915271
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: March 29, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Zhijian Lu, Peter J. Sinclair, Yi-Heng Chen, Cameron J. Smith, Hong Li
  • Patent number: 7910592
    Abstract: Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: March 22, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Zhijian Lu, Peter J. Sinclair, Yi-Heng Chen, Cameron J. Smith, Hong Li, Christopher F. Thompson
  • Publication number: 20110033451
    Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease).
    Type: Application
    Filed: June 30, 2010
    Publication date: February 10, 2011
    Applicant: Wyeth LLC
    Inventors: Beatriz M. Carreno, Mary Collins, Jill F. Wright, Neil M. Wolfman, Maya Arai, Kenneth Jacobs, Zhijian Lu, Yongjing Guo, Yongchang Qiu
  • Publication number: 20100302641
    Abstract: A large mask with random apertures may be formed by forming a smaller mask (also called a cell mask) with a random pattern of transmissive apertures which is then repeatedly replicated to create the large mask. The random pattern may be created by perturbing the aperture locations by a small amount or the apertures may be randomly placed within the cell mask provided certain criteria are met. Alternatively, a large mask with a random pattern of transmissive apertures may be formed without using a cell mask. This large mask may be used to fabricate diffusers and other devices that do not suffer from the interference, diffraction and other optical effects common in devices having structures that are non-randomly patterned.
    Type: Application
    Filed: August 10, 2010
    Publication date: December 2, 2010
    Inventor: Zhijian Lu
  • Patent number: 7842376
    Abstract: Diffusers including of a plurality of protruded structures with each structure containing multiple rugged facets are disclosed. The diffuser may be fabricated by coating a mixture of materials on a carrier film, the mixture of materials including at least a first material that polymerizes upon irradiation and at least a second material that is incompatible with the first material in polymerized form, then selectively irradiating the mixture of materials to polymerize a portion of the mixture of materials to form polymerized structures, and finally removing that part of the mixture of materials not forming part of the structures. A transparent material may be coated over the structures. The overcoat material may further contain scattering elements such as glass beads or polymeric particles.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: November 30, 2010
    Inventor: Zhijian Lu
  • Patent number: 7838204
    Abstract: A large mask with random apertures may be formed by forming a smaller mask (also called a cell mask) with a random pattern of transmissive apertures which is then repeatedly replicated to create the large mask. The random pattern may be created by perturbing the aperture locations by a small amount or the apertures may be randomly placed within the cell mask provided certain criteria are met. Alternatively, a large mask with a random pattern of transmissive apertures may be formed without using a cell mask. This large mask may be used to fabricate diffusers and other devices that do not suffer from the interference, diffraction and other optical effects common in devices having structures that are non-randomly patterned.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: November 23, 2010
    Inventor: Zhijian Lu
  • Publication number: 20100286071
    Abstract: Members of the TGF-? superfamily and peptide fragments based on member proteins are employed to purify solutions containing member proteins or as therapeutics.
    Type: Application
    Filed: June 17, 2010
    Publication date: November 11, 2010
    Applicant: Wyeth LLC
    Inventors: Zhijian Lu, Wei Liu, Jimin Zhang, Paul John Yaworsky, Stephane H. Olland, Christopher Todd Brown, Emily Sheng-ming Shen
  • Publication number: 20100249024
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
    Type: Application
    Filed: June 14, 2010
    Publication date: September 30, 2010
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Joann Bohn, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle E. Taylor, Christopher F. Thompson, Nazia Quraishi
  • Patent number: 7781426
    Abstract: Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B or R2 is a phenyl group which has an ortho amine or aminomethyl substituent which is further substituted, and the other of B or R2 is also a cyclic group.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: August 24, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Zhijian Lu, Peter J. Sinclair, Gayle E. Taylor, Christopher F. Thompson, Cameron J. Smith, Adrian A. Dowst, Yi-Heng Chen
  • Patent number: 7754689
    Abstract: Members of the TGF-? superfamily and peptide fragments based on member proteins are employed to purify solutions containing member proteins or as therapeutics.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: July 13, 2010
    Assignee: Wyeth LLC
    Inventors: Zhijian Lu, Wei Liu, Jimin Zhang, Paul John Yaworsky, Stephane H. Olland, Christopher Todd Brown, Emily Sheng-ming Shen
  • Patent number: 7737295
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: June 15, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Joann Bohn, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle E. Taylor, Christopher F. Thompson, Nazia Quraishi
  • Publication number: 20100112490
    Abstract: A large mask with random apertures may be formed by forming a smaller mask (also called a cell mask) with a random pattern of transmissive apertures which is then repeatedly replicated to create the large mask. The random pattern may be created by perturbing the aperture locations by a small amount or the apertures may be randomly placed within the cell mask provided certain criteria are met. Alternatively, a large mask with a random pattern of transmissive apertures may be formed without using a cell mask. This large mask may be used to fabricate diffusers and other devices that do not suffer from the interference, diffraction and other optical effects common in devices having structures that are non-randomly patterned.
    Type: Application
    Filed: November 23, 2009
    Publication date: May 6, 2010
    Inventor: Zhijian Lu
  • Publication number: 20100099716
    Abstract: Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
    Type: Application
    Filed: November 25, 2009
    Publication date: April 22, 2010
    Inventors: Amjad ALI, Joann M. Napolitano, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle E. Taylor, Christopher F. Thompson, Nazia Quraishi, Cameron J. Smith, Julianne A. Hunt, Adrian A. Dowst, Yi-Heng Chen, Hong Li
  • Patent number: 7670726
    Abstract: A large mask with random apertures may be formed by forming a smaller mask (also called a cell mask) with a random pattern of transmissive apertures which is then repeatedly replicated to create the large mask. The random pattern may be created by perturbing the aperture locations by a small amount or the apertures may be randomly placed within the cell mask provided certain criteria are met. Alternatively, a large mask with a random pattern of transmissive apertures may be formed without using a cell mask. This large mask may be used to fabricate diffusers and other devices that do not suffer from the interference, diffraction and other optical effects common in devices having structures that are non-randomly patterned.
    Type: Grant
    Filed: July 20, 2006
    Date of Patent: March 2, 2010
    Inventor: Zhijian Lu
  • Patent number: 7652049
    Abstract: Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: January 26, 2010
    Assignee: Merck & Co., Inc.
    Inventors: Amjad Ali, Joann M. Napolitano, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle E. Taylor, Christopher F. Thompson, Nazia Quraishi, Cameron J. Smith, Julianne A. Hunt, Adrian A. Dowst, Yi-Heng Chen, Hong Li
  • Patent number: 7590228
    Abstract: A general charging method includes establishing a charging strategy and performing the charging according to the charging strategy. The charging strategy includes at least one priority each of which includes at least one time period and each of the time periods is provided at least one rate segment in each of which there is at least one rate. Performing the charging includes: matching with a corresponding charging strategy upon the time a subscriber uses a service and/or the subscriber's current resource, and determining a charging mode; searching for a corresponding priority; performing the charging according to the charging mode. With such a structure of general charging strategy, the method can satisfy various charging demands and provide generality and adequate expansibility. Also, the method enables subscribers to configure different charging methods as necessary.
    Type: Grant
    Filed: November 8, 2007
    Date of Patent: September 15, 2009
    Assignee: Huawei Technologies Co., Ltd.
    Inventors: Zhijian Lu, Xin Zhang, Xiaozheng Guo, Qingchen Chu, Youkun Chen
  • Publication number: 20090226628
    Abstract: Diffusers including of a plurality of protruded structures with each structure containing multiple rugged facets are disclosed. The diffuser may be fabricated by coating a mixture of materials on a carrier film, the mixture of materials including at least a first material that polymerizes upon irradiation and at least a second material that is incompatible with the first material in polymerized form, then selectively irradiating the mixture of materials to polymerize a portion of the mixture of materials to form polymerized structures, and finally removing that part of the mixture of materials not forming part of the structures. A transparent material may be coated over the structures.
    Type: Application
    Filed: May 27, 2008
    Publication date: September 10, 2009
    Inventor: Zhijian Lu
  • Publication number: 20090221035
    Abstract: The invention relates to systems and methods for producing proteins of interest. The invention employs genetically-engineered animal or plant cells that have modified protein folding or processing capacities. In one aspect, the invention features genetically-engineered cells comprising one or more recombinant expression cassettes which encode (1) a protein of interest and (2) a polypeptide that is functional in the unfolded protein response (UPR) pathway of the cells. Co-expression of the polypeptide significantly increases the yield of the protein of interest in the genetically-engineered cells. In one example, the genetically-engineered cells are animal cells, and the co-expressed polypeptide is a component or modulator of an XB1- or ATF6-mediated UPR pathway.
    Type: Application
    Filed: April 6, 2009
    Publication date: September 3, 2009
    Applicant: WYETH
    Inventors: Yijie Gao, Nicole M. Piche, Mei Geng, Stephen H. Herrmann, Xiaotian Zhong, Ronald Kriz, Zhijian Lu
  • Publication number: 20090142806
    Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease).
    Type: Application
    Filed: August 21, 2008
    Publication date: June 4, 2009
    Applicant: WYETH
    Inventors: BEATRIZ M. CARRENO, MARY COLLINS, JILL F. WRIGHT, NEIL M. WOLFMAN, MAYA ARAI, KENNETH JACOBS, ZHIJIAN LU, YONGJING GUO, YONGCHANG QIU